Feed aggregator

Takeda Pulls Lung Cancer Drug After Confirmatory Trial Misses Primary Endpoint

Biospace news - Tue, 10/03/2023 - 02:00
Takeda Pulls Lung Cancer Drug After Confirmatory Trial Misses Primary Endpoint 10/3/2023

Boehringer Offers Unbranded Biosimilar at 81% Discount to AbbVie’s Humira

Biospace news - Tue, 10/03/2023 - 02:00
Boehringer Offers Unbranded Biosimilar at 81% Discount to AbbVie’s Humira 10/3/2023

Novartis Clears Phase III in IgAN, Eyes Regulatory Path for Complement Inhibitor

Biospace news - Tue, 10/03/2023 - 02:00
Novartis Clears Phase III in IgAN, Eyes Regulatory Path for Complement Inhibitor 10/3/2023

Syndax Ends Pivotal Leukemia Trial Early as Drug Meets Primary Endpoint

Biospace news - Tue, 10/03/2023 - 02:00
Syndax Ends Pivotal Leukemia Trial Early as Drug Meets Primary Endpoint 10/3/2023

Pfizer’s Biohaven Bet Pays Off Again as Migraine Nasal Spray Wins Approval

Biospace news - Tue, 10/03/2023 - 02:00
Pfizer’s Biohaven Bet Pays Off Again as Migraine Nasal Spray Wins Approval 3/10/2023

Independent Panel Recommends Polivy in First Line LBCL Despite FDA Reservations

Biospace news - Tue, 10/03/2023 - 02:00
Independent Panel Recommends Polivy in First Line LBCL Despite FDA Reservations 3/10/2023

FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues

Biospace news - Mon, 10/02/2023 - 02:00
FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues 10/2/2023

Federal Judge Denies Request to Block Medicare Drug Price Negotiation Program

Biospace news - Mon, 10/02/2023 - 02:00
Federal Judge Denies Request to Block Medicare Drug Price Negotiation Program 10/2/2023

Lexeo, Abivax File for IPOs on Nasdaq Amid Industry-Wide Drought

Biospace news - Mon, 10/02/2023 - 02:00
Lexeo, Abivax File for IPOs on Nasdaq Amid Industry-Wide Drought 10/2/2023

Parkinson’s Research Buoyed by Alzheimer’s Advances

Biospace news - Mon, 10/02/2023 - 02:00
Parkinson’s Research Buoyed by Alzheimer’s Advances 10/2/2023

FDA Action Alert: Amgen, Alnylam and BMS

Biospace news - Mon, 10/02/2023 - 02:00
FDA Action Alert: Amgen, Alnylam and BMS 10/2/2023

Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon

Biospace news - Fri, 09/29/2023 - 02:00
Path for BrainStorm ALS Treatment Remains Rocky, Hope for Others on Horizon 9/29/2023

Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs

Biospace news - Fri, 09/29/2023 - 02:00
Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs 9/29/2023

Bionomics’ PTSD Candidate Clears Phase IIb Study, Stock Jumps 415%

Biospace news - Fri, 09/29/2023 - 02:00
Bionomics’ PTSD Candidate Clears Phase IIb Study, Stock Jumps 415% 9/29/2023

Fabre-Kramer Finally Gets FDA Approval for MDD Drug After Decades-Long Quest

Biospace news - Fri, 09/29/2023 - 02:00
Fabre-Kramer Finally Gets FDA Approval for MDD Drug After Decades-Long Quest 9/29/2023

GSK Raises HIV Business Forecast on Projected Growth of Long-Acting Antiretroviral

Biospace news - Fri, 09/29/2023 - 02:00
GSK Raises HIV Business Forecast on Projected Growth of Long-Acting Antiretroviral 9/29/2023

Amicus Gets FDA Approval for Rare Muscle Disorder Treatment

Biospace news - Fri, 09/29/2023 - 02:00
Amicus Gets FDA Approval for Rare Muscle Disorder Treatment 9/29/2023

Four Neurodegenerative Trials to Watch in Q4

Biospace news - Fri, 09/29/2023 - 02:00
Four Neurodegenerative Trials to Watch in Q4 9/29/2023

J&J’s Rybrevant in Combo with Lazertinib Clears Phase III in NSCLC

Biospace news - Thu, 09/28/2023 - 02:00
J&J’s Rybrevant in Combo with Lazertinib Clears Phase III in NSCLC 9/28/2023

Karuna Submits Highly Anticipated NDA for KarXT in Schizophrenia

Biospace news - Thu, 09/28/2023 - 02:00
Karuna Submits Highly Anticipated NDA for KarXT in Schizophrenia 9/28/2023